What we do: Synexa Life Sciences is an early pioneer in the new field of biomarker services. Bio-marking is known as using a substance which causes a reaction that that indicates the presence of a living organism. Synexa Life Sciences has grown to offer a comprehensive range of analytical and advisory services to global biopharmaceutical companies focused on the identification, development, analysis and interpretation of biomarkers in clinical trials and diagnostic validation programs. The company was established in 2003.
Ownership & Management: Synexa Life Sciences was founded by Professor Patrick Bouic and Dr. Justin Devine who are both have longstanding experience in the medical and pharmaceutical industry. The company has since been operating with a strategic investor, the Industrial Development Corporation (IDC). Synexa Life Sciences is managed by a strong management team and has barriers to entry given the complexity of the pharmaceutical regulatory environment.
Key financial indicators: Synexa offers deep expertise in biomarker selection and panel design for each phase of clinical development. The company’s biomarker programs are tailor-made to customer requirements with up-front scientific collaboration. Audited financials are not available to the public.
Track record: Synexa Life Sciences operates in Cape Town (South Africa), Berlin (Germany), Dublin (Ireland) and London (UK) and the proven track record as a biomarker is undisputed.
Contact details: Tel: (+27) 21 933 9580 Email: email@example.com Address: 4 Kunene Circle, Omuramba Business Park, Omuramba Road, Montague Gardens, Cape Town, South Africa Website: http://www.synexagroup.com
Or contact us for free additional information at firstname.lastname@example.org